Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

(2017) Shuguang Tan et al.   Nature Communications

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

(2017) Fei Zhang et al.   Cell Discovery

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)

(2016) J. M. Kim et al.   ANNALS OF ONCOLOGY

The Basis of Oncoimmunology

(2016) A. Karolina Palucka et al.   CELL

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

(2016) Kefang Liu et al.   CELL RESEARCH

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

(2016) Zhenkun Na et al.   CELL RESEARCH

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

(2016) Scott Antonia et al.   LANCET ONCOLOGY

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

(2016) Ju Yeon Lee et al.   Nature Communications

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies

(2016) Shuguang Tan et al.   Protein & Cell

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

(2015) Roy L. Maute et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE